SOUTH SAN FRANCISCO, Calif. (AP) ¿ Rigel Pharmaceuticals Inc. said Tuesday its third-quarter loss narrowed as the development-stage biotechnology company completed two midstage studies in its rheumatoid-arthritis program.

The company lost $26.7 million, or 70 cents per share, compared with a loss of $37.7 million, or $1.03 per share, a year ago. There was no reported revenue during either quarter and the company still does not have a product on the market.

Analysts polled by Thomson Reuters, on average, expected a loss of 58 cents per share on revenue $3.8 million.

Rigel said stock-based compensation fell by about half, while operating expenses fell 31 percent to $26.7 million.

The company ended the quarter with cash, cash equivalents and available for sale securities of $156.1 million.

Rigel is developing treatments for rheumatoid arthritis, asthma, allergies and cancer. Partners on various programs include Serono SA, Pfizer Inc. and Merck & Co.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform